IGF1 and cancer: In particular, in several cancer cells from thyroid (98), liver (95, 111), colon (115), breast (115), lung (116, 117), and pancreas (118), PPAR-γ agonists inhibit IGF-I mediated biological effects through the reduction in Akt phosphorylation, increased PTEN expression levels (115), and inhibition of mTOR and p70S6K activity (116–120).